GlaxoSmithKline (GSK) Price Target Lowered to GBX 1,400 at Morgan Stanley

GlaxoSmithKline (LON:GSK) had its price objective decreased by Morgan Stanley from GBX 1,450 ($19.52) to GBX 1,400 ($18.84) in a report released on Friday. Morgan Stanley currently has an underweight rating on the stock.

A number of other research analysts also recently weighed in on the stock. Societe Generale reaffirmed a sell rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Berenberg Bank decreased their target price on shares of GlaxoSmithKline from GBX 1,835 ($24.70) to GBX 1,760 ($23.69) and set a buy rating for the company in a research report on Thursday, November 2nd. Deutsche Bank set a GBX 1,610 ($21.67) target price on shares of GlaxoSmithKline and gave the company a neutral rating in a research report on Friday, October 27th. Barclays reaffirmed an equal weight rating and issued a GBX 1,450 ($19.52) target price on shares of GlaxoSmithKline in a research report on Friday, October 27th. Finally, J P Morgan Chase & Co decreased their target price on shares of GlaxoSmithKline from GBX 1,570 ($21.13) to GBX 1,330 ($17.90) and set a neutral rating for the company in a research report on Sunday, October 29th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of Hold and an average target price of GBX 1,581.90 ($21.29).

Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,290.50 ($17.37) on Friday. GlaxoSmithKline has a twelve month low of GBX 1,277.50 ($17.19) and a twelve month high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping analysts’ consensus estimates of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%.

The business also recently announced a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be issued a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.

In related news, insider Urs Rohner bought 473 shares of GlaxoSmithKline stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($20.43) per share, with a total value of £7,180.14 ($9,663.71). Also, insider Simon Dingemans bought 1,076 shares of GlaxoSmithKline stock in a transaction that occurred on Thursday, October 12th. The shares were bought at an average cost of GBX 1,527 ($20.55) per share, with a total value of £16,430.52 ($22,113.76). Insiders have purchased a total of 1,576 shares of company stock valued at $2,400,376 in the last ninety days.

WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/05/glaxosmithkline-gsk-price-target-lowered-to-gbx-1400-at-morgan-stanley.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply